



Press Release

The ETICS project, led by CYTOO in collaboration with Collectis bioresearch and the CEA, to receive €7.6 million in aid from OSEO

A collaboration to develop highly innovative kits for pharmaceutical research

Paris, September 26, 2011 - CYTOO, a company that specializes in cell-based assays (Grenoble, France), has joined up with Collectis bioresearch, the specialist in genome customization and commercial subsidiary of Collectis (Alternext: ALCLS), and the CEA, the French Alternative Energies and Atomic Energy Commission, to develop new high-value cell-based assays for drug development and toxicology.

The project, named ETICS¹, will focus on the development of cell-based assays, which will be commercialized as kits, comprising cells genetically modified by Collectis bioresearch and CYTOO's micropatterned supports. By controlling the expression, the architecture and the 2D and 3D environment of the cells, thus mimicking *in vivo* conditions of the tissue they derive from (liver, heart...), these assays will have much higher relevance to discover better and safer drugs.

OSEO, the French agency supporting innovation, is providing €7.6 million in funding for the ETICS project for the next 5 years, including €4 million for CYTOO, €2.9 million for Collectis bioresearch and €0.7 million for the CEA. This project could generate over €600 million for the consortium in ten years.

« *The three partners of the ETICS project have complementary know-how and synergies in the key domains for the success of such a project* », said François Chatelain, Chairman and CEO of CYTOO.

"*This funding will enable us to extend our product offering and to win market shares from our major North American competitors*", stated Marc Le Bozec, Collectis bioresearch CEO. "*I would like to congratulate the ETICS partners and OSEO teams for the quality of work accomplished, which we believe will yield an important advancement in the development of new drugs*".

¹ ETICS stands for « Evolved Tissue Inspired Cell Systems »

About the “Industrial Strategic Innovation” Program from OSEO

The « Industrial Strategic Innovation » (ISI) program supports the emergence of European champions. It supports ambitious projects of collaborative innovation for the industry, carried by innovative medium-size companies (under 5.000 employees) and SMEs (under 250 employees). These projects hold a lot of promise: they aim at the commercialization of technological breakthrough products, and could not succeed without public support. The funding is usually comprised between €3 million and €10 million, in the form of subventions and reimbursable loans.

About Collectis bioresearch

Collectis bioresearch was incorporated as a subsidiary of Collectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on sequence specific nucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies. The genome customization products and services can be purchased online from www.collectis-bioresearch.com. Check the website for more information.

Follow Collectis bioresearch on Twitter: <http://twitter.com/genengineer>

About Collectis

Collectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Collectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

For further information about Collectis, visit our website at: www.collectis.com

Follow Collectis on Twitter: <http://twitter.com/collectis>

About CYTOO

CYTOO is a distinctive Life Sciences Systems/ Tools enabling company that currently offers a disruptive solution that brings robustness, sensitivity and powerful quantification to cell-based assays and High Content Screening (HCS). The technology offers exquisite control over the cells' microenvironment, leading to normalized cell morphology and behavior. CYTOO is engaged in developing, manufacturing and commercializing innovative products to the Life Sciences research community (industry and academia). The Company has tailored a portfolio of innovative products using its proprietary cell adhesive micropattern technologies to target first its fast growing High Content Screening and Analysis segment within the large cell biology market

www.cytoo.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Collectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements.

For further information, please contact:

Collectis

Sylvie Delassus
Senior VP Corporate Communication
Tel: +33 (0)1 41 83 99 00
Cell: +33 (0)6 26 54 33 18
media@collectis.com

CYTOO

Alexandra Fuchs
COO
Tel : +33 (0)4 38 88 47 07
afuchs@cytoo.com